Cabanes-Creus, Marti
Liao, Sophia H. Y.
Gale Navarro, Renina
Knight, Maddison
Nazareth, Deborah
Lau, Ngee-Soon
Ly, Mark
Zhu, Erhua
Roca-Pinilla, Ramon http://orcid.org/0000-0002-7393-6200
Bugallo Delgado, Ricardo
Vicente, Ana F.
Baltazar, Grober
Westhaus, Adrian http://orcid.org/0000-0001-6439-4326
Merjane, Jessica
Crawford, Michael
McCaughan, Geoffrey W.
Unzu, Carmen http://orcid.org/0000-0002-1582-7196
González-Aseguinolaza, Gloria http://orcid.org/0000-0002-1600-4562
Alexander, Ian E. http://orcid.org/0000-0002-6213-5627
Pulitano, Carlo http://orcid.org/0000-0002-4420-4107
Lisowski, Leszek http://orcid.org/0000-0002-4772-8651
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP2021305, APP1161583)
Narodowe Centrum Nauki (OPUS-21 (2021/41/B/NZ5/01671))
Article History
Received: 11 July 2023
Accepted: 19 February 2024
First Online: 14 March 2024
Competing interests
: L.L. and I.E.A. are co-founders of Exigen Biotherapeutics, a company that utilizes similar technologies broadly discussed in this paper. M.C.-C., I.E.A., and L.L. are inventors on patent applications filed by Children’s Medical Research Institute related to AAV capsid sequences and in vivo function of novel AAV variants (WO2021168509). The remaining authors declare no competing interests.